Mutations in the BRCA1 and BRCA2 genes are associated with hereditary breast and ovarian cancer. Genetic testing is available in specialised laboratories, but is expensive and presents a significant technical and interpretative challenge. Identification of a causative mutation carries lifelong health and psychosocial implications for the woman and her relatives. It also influences surveillance and treatment options. Testing should therefore only be considered with professional genetic counselling by specialists in familial cancer clinics.
Introduction
Breast cancer is the most common form of cancer among women in Australia. A woman has approximately a 1 in 10 chance of developing breast cancer at some point in her life. Most of these breast cancers are sporadic, reflecting the inevitable accumulation of errors in a person's DNA with age.
However, 5-10% of affected women have a strong underlying and heritable predisposition to develop breast cancer.
Mutations in many different genes can cause a predisposition to develop breast cancer. For most women with familial breast cancer, the causative mutation is unknown and cannot be identified. However, the mutations most commonly identified in women with familial breast cancer are breast cancer susceptibility gene 1 (BRCA1) and breast cancer susceptibility gene 2 (BRCA2). Together these mutations are found in approximately 20% of cases (that is, 1-2% of all breast cancers).
Mutations in other genes, for example, TP53, CDH1, PTeN and STK11, are associated with rare genetic syndromes which can also predispose to breast cancer.
BRCA1 and BRCA2 genes
The BRCA1 gene is found on chromosome 17 and the BRCA2 gene is found on chromosome 13. They are tumour suppressor genes. The proteins encoded by these genes are part of a multi-protein complex which repairs damaged DNA. The complex normally repairs double-strand breaks in the DNA by homologous recombination. A cell which has lost BRCA1 or BRCA2 activity is unable to repair this damage and can rapidly accumulate mutations which eventually lead to cancer. 1 A heritable mutation in either gene greatly increases the chance that a cell will become malignant. These mutations are inherited as autosomal dominants and there is a 50% chance that a child will inherit the abnormal gene from a carrier parent. The child will also inherit a normal copy of the gene from the other parent which will function, but the cell lacks a backup should this normal copy fail. With the inevitable accumulation of genetic errors with age, the normal copy may eventually become mutated (sometimes called the 'second hit') and the cell is left with no functioning BRCA gene. The resulting rapid accumulation of uncorrected errors in the cell's DNA usually leads to cancer.
For reasons that are not clear, the loss of BRCA1 or BRCA2 function increases the risk of some but not all cancers. Female carriers of a mutation in BRCA1 or BRCA2 are at high risk of developing breast cancer and ovarian cancer, while male carriers are at increased risk of breast and prostate cancer. In addition there is also a slightly increased risk of a wide range of other cancers, but the predominant cancer risk by far is that of breast and ovarian cancer. 1 It is possible for someone to carry both a BRCA1 and BRCA2 mutation (double heterozygote) but this is very rare, accounting for less than 1% of all BRCA mutation carriers. For reasons that are not clear, double heterozygotes do not have a higher risk of cancer nor more severe disease compared to single mutation carriers. For men, the principal reason for knowing their carrier status is to clarify the risk of their daughters inheriting the mutation.
Indications for BRCA testing

Management
The main benefit of finding the familial BRCA mutation is the prevention or early detection of cancer in at-risk relatives. The The book also provides useful summaries of the latest management guidelines of important and diverse conditions, such as when to recommend symptomatic treatment of otitis media rather than antibiotic treatment, and the procedures requiring antibiotics for the prevention of endocarditis.
A change in structure in this edition has led to the removal of some sections which overlapped with other Therapeutic Guidelines editions. Some readers may be disappointed to find that some common gastroenterological, dermatological or respiratory conditions requiring antimicrobial management are no longer included in this book, with the reader being directed to other books in the series.
I recommend this book to busy clinicians, which is just about all of us! It is an essential guide to prescribing antimicrobials, although the electronic version, as part of the complete set, may be necessary to get a more complete coverage of the clinical scenarios the reader will face.
